AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01500746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse lavage treatment
Description: A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
Study NCT01500746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing changes
Description: Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
Study NCT01079624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-insulinotropic peptide, Glucagon-like peptide-1
Description: GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Study NCT01079624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose-insulinotropic peptide, Glucagon-like peptide-1
Description: GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Study NCT01622712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebound HRD Mesh
Description: Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
Study NCT02334527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: 125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
Study NCT01706965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: 20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
Study NCT01706965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multi-vitamin will be used as an active control in this study. Will be dosed daily
Study NCT02538679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The usual intraoperative and postoperative pain control; NO TAP block performed
Study NCT02538679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US TAP Bupivacaine/Epinephrine
Description: Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
Study NCT02538679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lap TAP Bupivacaine/Epinephrine
Description: Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
Study NCT04410328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care
Description: Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
Study NCT04410328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
Study NCT04410328 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
Study NCT01563978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily
Study NCT01563978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00324012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, taxotere
Description: cisplatin 75 mg/m2 Taxotere 75 mg/m2
Study NCT00660920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Comparison of different dosages of drug given orally once per day.
Study NCT03698864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS499
Description: PCS499 900mg twice a day with food
Study NCT05085743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep convolutional neural networks analysis
Description: using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
Study NCT03133949 — intervention group
Intervention type: OTHER
Intervention: Establish the clinical, biological and radiological characteristics of patients
Description: Establish the clinical, biological and radiological characteristics of patients
Study NCT01717183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgo 310 3113
Description: URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
Study NCT01717183 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo URGO 310 3113 dressing
Study NCT04533776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celiac Disease Definition, Symptoms and Treatment
Description: * Adolescents share their knowledge about the disease~* Emphasizing the definition and symptoms of celiac disease~* Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing
Study NCT04533776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Difficulties Due to Celiac Disease
Description: * Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~* Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~* Determining how the disease affects life Expression Question-Answer Discussion Summarizing
Study NCT04533776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet in Celiac Disease
Description: * Evaluating dietary information~* Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)
Study NCT04533776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Difficulties Related to Disease in School and Social Life
Description: * Assessment of difficulties encountered in school and social life~* Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)
Study NCT04533776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celiac Disease and Its Effects on Acamdemic Success Peer Relations
Description: * Evaluation of the effects of the disease on academic success~* Evaluation of the effects of the disease on peer relationships in the school enviroment~* Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing
Study NCT04533776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celiac Diseae anf Future Goals
Description: * General summary of all sessions so far~* Summarizing the topics discussed in the previous session~* Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing
Study NCT04533776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention: routine health care- control group
Description: Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
Study NCT01647308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISIS-APOCIIIRX
Description: 3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
Study NCT01647308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
Study NCT03164915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIV-GAMMA SN Inj.
Study NCT02155959 — intervention group
Intervention type: DEVICE
Intervention: toric intraocular lens
Description: toric intraocular lens
Study NCT00859092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Simply Thick
Description: Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
Study NCT03116503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnosis of bipolar disorder and comorbid depression
Description: Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
Study NCT01409421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: counseling intervention
Study NCT01409421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: three phone calls to remind patients to take their eye drops
Description: reminder phone calls
Study NCT00216320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WalkAide
Description: Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
Study NCT00216320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WalkAide
Description: Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
Study NCT00216320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AFO
Description: Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
Study NCT00216320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFO
Description: Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
Study NCT00216320 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AFO
Description: Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
Study NCT01730014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 148-0287-A-4.2mM-cartridge
Description: In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
Study NCT01730014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
Study NCT01730014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 148-0287-A-4.2mM-cartridge
Description: In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
Study NCT01730014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
Study NCT01730014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
Study NCT01730014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride 0.9% w/v
Description: In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
Study NCT00593320 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Study NCT02333734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces \~ 90% of the maximum heart rate. The time spent per session is expected to last \~ 25 minutes.
Study NCT04248465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Study NCT04248465 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ravulizumab
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Study NCT04248465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Study NCT01173640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg oral dose
Study NCT01287845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1075553
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 6 and fIPV at 22 weeks, Rotarix
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 6 and fIPV at 22 weeks, RotaTeq
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV at 6-14-22 weeks of age, Rotarix
Description: Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
Study NCT02847026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV at 6-14-22 weeks of age, RotaTeq
Description: Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
Study NCT00380718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity\* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~\*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets \<50 x 10\^9/L; absolute neutrophil count \<1.0 x 10\^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade >2; Skin Grade >2; Serum bilirubin >3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase >10 x ULN; Other non-hematologic toxicities Grade >2 (except nausea, vomiting).
Study NCT00659542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate glue
Description: 1 ml glue
Study NCT03009383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A bedside portable endoscopy
Study NCT03765112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography
Description: Multiple scans of the retina will be recorded to evaluate microvascular changes.
Study NCT01886781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Description: two capsules of 5 X 10 \^9 c.f.u each
Study NCT01886781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Micro-crystalline cellulose powder, identical taste, texture and appearance
Study NCT01886781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Run in period
Description: Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
Study NCT01287845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1075553
Description: Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Study NCT03065439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static balance testing
Description: Postural sway will be measured using a force plate (Metitur Good Balance System®).
Study NCT00951678 — intervention group
Intervention type: OTHER
Intervention: Observational ultrasonography of venous anatomy
Description: The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
Study NCT03111797 — intervention group
Intervention type: DRUG
Intervention: Morphine
Description: we observe the self-patient controlled morphine consumption during the first 48h after surgery
Study NCT03111797 — intervention group
Intervention type: OTHER
Intervention: Cardiac output measure
Description: we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
Study NCT00338988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m\^2 PO twice daily x 14 days.
Study NCT00338988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 IV over 2 hours on day 1 of cycle.
Study NCT01886781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Run in period
Description: Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
Study NCT01886781 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wash - out period
Description: Wash - out period following treatment phase of eight weeks
Study NCT01886781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash - out period
Description: Wash - out period following treatment phase of eight weeks
Study NCT00664794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without acromioplasty
Description: This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
Study NCT00664794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with acromioplasty
Description: This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
Study NCT00970424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, oral tablet administered once daily on background of pioglitazone
Study NCT00970424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutogliptin
Description: dutogliptin, oral tablet administered once daily on background of pioglitazone
Study NCT01484860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
Study NCT00528632 — intervention group
Intervention type: OTHER
Intervention: Specimen biopsy and serum laboratory tests
Description: Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides
Study NCT01864213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ametop cream
Study NCT02358772 — intervention group
Intervention type: OTHER
Intervention: thrombolysis in a pre-hospital setting (STEMO concept)
Study NCT01074151 — intervention group
Intervention type: DRUG
Intervention: duloxetine
Description: any exposure to duloxetine that occurred during pregnancy
Study NCT01395173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position change
Description: Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
Study NCT01395173 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
Study NCT00780624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator is Bird VIP.
Study NCT01431950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate
Description: Inhaled corticosteroid
Study NCT01431950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Provided as rescue relief of asthma symptoms
Study NCT03819842 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pseudophakic Measurement
Description: standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
Study NCT03462368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.